Next Article in Journal
Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance
Next Article in Special Issue
Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer
Previous Article in Journal
Computational Model Reveals a Stochastic Mechanism behind Germinal Center Clonal Bursts
Previous Article in Special Issue
Androgen Deprivation Induces Reprogramming of Prostate Cancer Cells to Stem-Like Cells
Open AccessReview

Cancer Stem Cells in Soft-Tissue Sarcomas

Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain
Health Research Institute of the Balearic Islands (IdISBa) and Molecular Diagnosis Unit, Son Espases University Hospital, 07120 Palma de Mallorca, Spain
Medical Oncology Department, University Hospital Virgen del Rocio, 41013 Seville, Spain
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2020, 9(6), 1449;
Received: 14 May 2020 / Revised: 6 June 2020 / Accepted: 8 June 2020 / Published: 10 June 2020
(This article belongs to the Special Issue Cancer Stem Cells and Resistance to Therapy)
Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic profiles and clinical features. Systemic chemotherapy is the backbone treatment for advanced STS; however, STS frequently acquire resistance to standard therapies, which highlights the need to improve treatments and identify novel therapeutic targets. Increases in the knowledge of the molecular pathways that drive sarcomas have brought to light different molecular alterations that cause tumor initiation and progression. These findings have triggered a breakthrough of targeted therapies that are being assessed in clinical trials. Cancer stem cells (CSCs) exhibit mesenchymal stem cell (MSC) features and represent a subpopulation of tumor cells that play an important role in tumor progression, chemotherapy resistance, recurrence and metastasis. In fact, CSCs phenotypes have been identified in sarcomas, allied to drug resistance and tumorigenesis. Herein, we will review the published evidence of CSCs in STS, discussing the molecular characteristic of CSCs, the commonly used isolation techniques and the new possibilities of targeting CSCs as a way to improve STS treatment and consequently patient outcome. View Full-Text
Keywords: cancer stem cells; tumor-initiating cells; soft-tissue sarcoma; chemotherapy resistance; stemness; tumor heterogeneity; genetic and epigenetic plasticity cancer stem cells; tumor-initiating cells; soft-tissue sarcoma; chemotherapy resistance; stemness; tumor heterogeneity; genetic and epigenetic plasticity
Show Figures

Figure 1

MDPI and ACS Style

Martínez-Delgado, P.; Lacerenza, S.; Obrador-Hevia, A.; Lopez-Alvarez, M.; Mondaza-Hernandez, J.L.; Blanco-Alcaina, E.; Sanchez-Bustos, P.; Hindi, N.; S. Moura, D.; Martin-Broto, J. Cancer Stem Cells in Soft-Tissue Sarcomas. Cells 2020, 9, 1449.

AMA Style

Martínez-Delgado P, Lacerenza S, Obrador-Hevia A, Lopez-Alvarez M, Mondaza-Hernandez JL, Blanco-Alcaina E, Sanchez-Bustos P, Hindi N, S. Moura D, Martin-Broto J. Cancer Stem Cells in Soft-Tissue Sarcomas. Cells. 2020; 9(6):1449.

Chicago/Turabian Style

Martínez-Delgado, Paula; Lacerenza, Serena; Obrador-Hevia, Antonia; Lopez-Alvarez, Maria; Mondaza-Hernandez, José L.; Blanco-Alcaina, Elena; Sanchez-Bustos, Paloma; Hindi, Nadia; S. Moura, David; Martin-Broto, Javier. 2020. "Cancer Stem Cells in Soft-Tissue Sarcomas" Cells 9, no. 6: 1449.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop